Early Diagnosis and Treatment Are Key to Better Outcomes in Rheumatoid Arthritis, Review Finds

An international review led by Josef S. Smolen of the Medical University of Vienna has found that early, consistently managed treatment can decisively change the course of rheumatoid arthritis and help prevent permanent joint damage. The analysis, published in the journal JAMA, summarizes evidence on the disease's causes, diagnosis, treatment and outlook.

Rheumatoid arthritis is a chronic autoimmune disease in which the immune system attacks the synovial membrane lining the joints, causing inflammation that can permanently damage cartilage and bone. For the review, researchers from the Medical University of Vienna and Stanford University screened 15,886 scientific publications, narrowing them to 120 studies for detailed analysis, including 43 randomized clinical trials, 28 cohort studies, 11 systematic reviews and 15 international guidelines.

The results show that timing is crucial: if the condition is detected ideally within six weeks of the first symptoms, treatment with disease-modifying antirheumatic drugs, which suppress inflammation and can prevent joint damage, tends to be particularly successful. Smolen said the treatment goal is at least a 50% reduction in disease activity within three months, and remission or low disease activity within six months.

Current European recommendations propose methotrexate as first-line therapy, often supplemented by a temporary course of glucocorticoids; around 40% of patients reach remission within six months using this approach. If that target is not met, adding biological agents or Janus kinase inhibitors, drugs that interfere with specific immune-system signals, raises the share of patients in remission or with low disease activity to around 80% over the course of the disease.

The study authors also stressed the value of a 'treat-to-target' approach, regularly monitoring disease activity with standardized tools and adjusting treatment early when needed, which has been shown to improve outcomes compared with routine care that lacks defined treatment targets.